Skip to main content

Talquetamab

Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma

  • RegistryNCT07093554
  • PhasePhase 1
  • StatusRecruiting
  • ConditionRelapsed/Refractory Multiple Myeloma
  • SponsorMedical College of Wisconsin
How Talquetamab worksNCT070935541 min

What the film says

Read the transcript

This trial is for multiple myeloma that has returned or not responded, in adults who have had at least one earlier line of therapy and are eligible for two approved treatments.

The idea: use the waiting time. After cells are collected, patients receive one cycle of talquetamab while their CAR T cells are manufactured. Then they receive lymphodepleting chemotherapy and the CAR T therapy cilta cel.

This phase 1b trial plans 31 patients and measures safety first. At the Medical College of Wisconsin in Milwaukee, Othman Akhtar leads it.

Public record; not medical advice.

Sources behind this film

  • ClinicalTrials.gov record NCT07093554

    Multiple myeloma returned or not responded, at least one earlier line, eligible for both commercial treatments; After cells are collected, one cycle of talquetamab while CAR T cells are manufactured; Then lymphodepleting chemotherapy and cilta cel; Phase 1b, 31 patients, safety first (+1 more lines)

The drug

What is being tested.

Talquetamab will be administered subcutaneously.

Ciltacabtagene Autoleucel will be administered intravenously.

This study will enroll patients with RRMM who have received at least one prior line of therapy and are eligible for both commercial talquetamab and cilta-cel. Patients will enroll prior to apheresis. Following apheresis, patients will receive one cycle of talquetamab therapy. An additional cycle of talquetamab will be allowed if manufacturing delays result in an expected lymphodepletion date > 4 weeks from the last full dose of talquetamab in Cycle 1.

The study

How the trial runs.

This is a single-arm, open-label, phase 1b study evaluating the safety and feasibility of using talquetamab as bridging therapy prior to cilta-cel in patients with relapsed and refractory multiple myeloma (RRMM).

Live record on ClinicalTrials.gov →

Eligibility

Who the study is looking for.

  • Histologically confirmed diagnosis of multiple myeloma with evidence of progressive disease as defined by the IMWG criteria.
  • Have measurable disease, defined as:
  • Serum M-protein level ≥ 1.0 g/dL, or
  • Urine M-protein level ≥ 200 mg/24 hours, or
  • In patients without a measurable M-protein, an involved light chain level ≥ 10 mg/dL and an abnormal free light chain ratio.
  • Patient had at least one prior line of therapy (PLOT), including a proteasome inhibitor (PI), an anti-CD38 antibody, and an immunomodulatory drug (IMID).

Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.

For you, or someone you love

Whether or not this trial is the one, bring AI into your corner.

A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.

Start your 7-day free trial

Then $9 a month. Cancel anytime.

  • Every record in one place

    Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.

  • Read in plain words

    Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.

  • Ready for every appointment

    Ask about your own file, and walk in with questions for your oncologist or the trial team.

  • Your people, in the loop

    Share one profile with the family helping you, and with your doctors.

Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.

How these trials work: what Phase 1 actually is · common questions Not clinical evidence.